# Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

> **NCT04956328** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** Obeticholic Acid Tablets
- **DRUG:** UDCA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04956328
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-22
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-09-20
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956328, "Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04956328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*